$RARE insider trading
Over the last 12 months, Ultragenyx Pharmaceutical insiders reported no purchases and 25 sales totaling $3.8M across SEC Form 4 filings. 48% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $3.8M 25 events
- Events · 12m
- 25 Form 4 filings, grouped
- Insiders · 12m
- 8 distinct reporters
- 10b5-1 share
- 48% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | Huizenga Theodore AlanSVP, Chief Accounting Officer · O | ▼ Sale | 1,283 | $13.57 | $17K | -1.9% | plan |
| Sep 3, 2026 | Huizenga Theodore AlanSVP, Chief Accounting Officer · O | ▼ Sale | 161 | $13.99 | $2K | -0.2% | — |
| Aug 3, 2026 | Parschauer Karah HerdmanEVP and Chief Legal Officer · O | ▼ Sale | 1,900 | $24.92 | $47K | -2% | plan |
| Aug 3, 2026 | Horn HowardChief Financial Officer · O | ▼ Sale | 4,696 | $24.92 | $117K | -4.6% | plan |
| Jul 1, 2026 | Horn HowardChief Financial Officer · O | ▼ Sale | 4,698 | $33.13 | $156K | -4.4% | plan |
| Jun 15, 2026 | Sanders Corazon (Corsee) D.D | ▼ Sale | 2,000 | $25.05 | $50K | -8.7% | — |
| Jun 15, 2026 | Parschauer Karah HerdmanEVP and Chief Legal Officer · O | ▼ Sale | 1,899 | $24.62 | $47K | -2% | plan |
| Jun 1, 2026 | Horn HowardChief Financial Officer · O | ▼ Sale | 4,653 | $23.77 | $111K | -4.2% | plan |
| May 5, 2026 | Crombez EricEVP and Chief Medical Officer · O | ▼ Sale | 344 | $24.96 | $9K | -0.3% | — |
| May 1, 2026 | Horn HowardChief Financial Officer · O | ▼ Sale | 4,683 | $24.9 | $117K | -4.1% | plan |
| Apr 1, 2026 | Horn HowardChief Financial Officer · O | ▼ Sale | 4,683 | $20.97 | $98K | -5.5% | plan |
| Mar 10, 2026 | Parschauer Karah HerdmanEVP and Chief Legal Officer · O | ▼ Sale | 9,526 | $21.87 | $208K | -12.5% | 2 tranches |
| Mar 3, 2026 | Horn HowardChief Financial Officer · O | ▼ Sale | 10,044 | $22.65 | $228K | -10.6% | plan · 3 tranches |
| Mar 2, 2026 | Pinion John RichardSee Remarks · O | ▼ Sale | 10,029 | $22.8 | $229K | -8.4% | — |
| Mar 2, 2026 | Harris ErikEVP & Chief Commercial Officer · O | ▼ Sale | 10,539 | $22.8 | $240K | -10.5% | — |
| Mar 2, 2026 | KAKKIS EMIL DPresident & CEO · O·D | ▼ Sale | 54,404 | $22.8 | $1.2M | -7.6% | — |
| Mar 2, 2026 | Parschauer Karah HerdmanEVP and Chief Legal Officer · O | ▼ Sale | 8,135 | $22.8 | $185K | -9.6% | — |
| Mar 2, 2026 | Huizenga Theodore AlanSVP, Chief Accounting Officer · O | ▼ Sale | 1,632 | $22.8 | $37K | -3.2% | — |
| Mar 2, 2026 | Crombez EricEVP and Chief Medical Officer · O | ▼ Sale | 7,029 | $22.8 | $160K | -8.4% | — |
| Feb 2, 2026 | Horn HowardChief Financial Officer · O | ▼ Sale | 3,061 | $23.56 | $72K | -3.3% | plan |
| Jan 2, 2026 | Horn HowardChief Financial Officer · O | ▼ Sale | 3,150 | $22.84 | $72K | -3.3% | plan |
| Dec 29, 2025 | Huizenga Theodore AlanSVP, Chief Accounting Officer · O | ▼ Sale | 85 | $34.38 | $3K | -0.2% | — |
| Dec 10, 2025 | Horn HowardChief Financial Officer · O | ▼ Sale | 3,081 | $36.38 | $112K | -3.1% | plan |
| Oct 13, 2025 | Horn HowardChief Financial Officer · O | ▼ Sale | 7,942 | $31.51 | $250K | -7.5% | — |
| Sep 18, 2025 | Huizenga Theodore AlanSVP, Chief Accounting Officer · O | ▼ Sale | 64 | $29.17 | $2K | -0.1% | — |
| Sep 12, 2025 | Parschauer Karah HerdmanEVP and Chief Legal Officer · O | ▼ Sale | 2,450 | $31.17 | $76K | -3.2% | — |
| Sep 5, 2025 | Huizenga Theodore AlanSVP, Chief Accounting Officer · O | ▼ Sale | 84 | $31.39 | $3K | -0.2% | — |
Every $RARE filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Ultragenyx Pharmaceutical filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $RARE feed.